Protagonist Therapeutics, Inc. (NASDAQ:PTGX) saw recent activity involving one of its directors. According to filings with the SEC, William D. Waddill sold shares of the company’s common stock on May 29, 2026.
Specifically, Mr. Waddill divested 9,000 shares of common stock at a price of $99.64 per share. The total value of this sale transaction amounted to $896,760. This divestment was executed using a 10b5-1 trading plan that had been adopted by Mr. Waddill on February 27, 2026.
It is noteworthy that the stock price has since experienced fluctuations; while it currently trades at $94.91, shares of PTGX have nonetheless delivered a reported 100% return over the past year. An analysis provided by InvestingPro suggests that the stock exhibits high volatility, yet analysts generally maintain a bullish outlook with established price targets reaching as high as $137.
Prior and Current Holdings Overview
Examining Mr. Waddill's activity leading up to the sale provides context for his current holdings. Before making the recent transaction, Mr. Waddill had acquired an additional 9,000 shares of common stock through the exercise of previously granted stock options. These options were exercised at a price point of $11.80 per share, resulting in a total cost basis of $106,200. The text confirms that these specific stock options were fully vested when they were exercised.
Following the recent sale and prior acquisitions, Mr. Waddill's direct ownership stake remains substantial. He currently holds 7,825 shares of Protagonist Therapeutics common stock. Additionally, he retains 3,000 outstanding stock options that are scheduled to expire on June 6, 2029.
Analyst Commentary and Platform Potential
Beyond the insider trading activity, Protagonist Therapeutics has recently been a focus of several analyst updates and strategic industry developments. This external validation points to strong growth potential for the company.
- Wolfe Research initiated coverage on Protagonist Therapeutics with an